Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy Xu

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Clinical Genitourinary Cancer|November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaYung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Clinical Genitourinary Cancer|November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaYung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.
Pageof 3